Certara, Inc. (Certara), a global leader in biosimulation, has announced the pricing of its upsized initial public offering of 29,055,000 shares of its common stock at US$23 per share. Certara is offering 14,630,000 shares of its common stock and certain selling stockholders are offering 14,425,000 shares of common stock in the offering. Shares of Certara’s common stock are expected to begin trading on The Nasdaq Global Select Market on December 11, 2020, under the ticker symbol “CERT,” and the offering is expected to close on December 15, 2020, subject to customary closing conditions. The selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 4,358,250 shares of common stock at the initial public offering price less the underwriting discounts and commissions. The gross proceeds to Certara from the offering will be approximately US$336.5 million, before deducting the underwriting discount and estimated offering expenses. Certara will not receive any proceeds from any sale of shares in the offering by the selling stockholders.
Latham & Watkins LLP represented the underwriters in the offering with a capital markets team led by Washington, D.C. partner Jason Licht and Boston/New York partner Wesley Holmes, with associates Christopher Clark, Isabel Rivera, Gabrielle Blum, and Jake Goodman.